Dr. Anca Bulgaru, MD

Dr. Bulgaru practices at Northeast Medical Group, Inc. in Waterford, Connecticut.

Dr. Bulgaru's NPI, 1659356640, was assigned on December 13, 2005. Dr. Bulgaru holds Connecticut license 041587.

Dr. Bulgaru's primary practice is Northeast Medical Group, Inc., at 230 Waterford S Pkwy, Waterford, CT 06385 in Southeastern Ct County. The practice phone is (203) 384-3975.

Dr. Bulgaru's primary practice is Northeast Medical Group, Inc. in Waterford, Connecticut. Dr. Bulgaru is also affiliated with Yale New Haven Hospital. The medical group on file is Northeast Medical Group. Dmand AI also links Dr. Bulgaru to 3 more hospitals, 1 group practice or clinic, 1 hospice and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Bulgaru practices, 6 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Bulgaru's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Bulgaru is licensed in Connecticut.

CMS data shows 1,350 Medicare services from Dr. Bulgaru across 13 procedure codes in 2024, for 376 Medicare patients. Medicare paid $86,178 for them.

CMS counts 376 Medicare patients who saw Dr. Bulgaru in 2024. The largest group is 65 to 74, with 142 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 23% are also on Medicaid. Their average risk score is 1.93, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Bulgaru's median patient age at 73, with 88% women.

In 2024, Dr. Bulgaru wrote 1,797 Medicare Part D claims for 354 patients. 78% of them were for generic drugs. CMS names the drug for 1,514 of them, across 35 drugs with 11 or more claims each, at $1,794,894 in total drug cost. In 2023, CMS named 1,302 claims across 32 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Bulgaru for performance year 2024, reported through an alternative payment model (APM). Dr. Bulgaru accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Bulgaru as offering telehealth.

Dmand AI links 1 paper to Dr. Bulgaru.

Dmand AI links Dr. Bulgaru to 3 clinical trials, 2 of them phase 3 studies. 2 are still active or recruiting. Conditions studied include Breast Neoplasms and Breast Diseases. Novartis Pharmaceuticals sponsors the most, 2.

CMS Open Payments shows 355 general payments to Dr. Bulgaru from 45 drug and device companies from 2016 to 2023. Food and beverage make up the largest share, 94% of the total. Novartis Pharmaceuticals Corporation paid the most, $740.